Clinical Trial Update: Use of 852A in Metastatic Cutaneous Melanoma. [Phase 2]

View source ↗

Summary

Pfizer completed a Phase 2 trial evaluating the agent 852A in patients with unresectable or metastatic cutaneous melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma

Drugs mentioned

• 852A

Snippet

Sponsor: Pfizer | Conditions: Melanoma, Unresectable Metatstatic Cutaneous Melanoma | Phase 2 | Status: COMPLETED